Anti-Human CD21 (Clone Bu32) – Purified (PhenoCycler-Fusion (CODEX)® Ready)

Myeloma cell line Rob

This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4.

This antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.

IHC,
FC

Bu32 activity is directed against human CD21.

CD21 is expressed on the surface of B lymphocytes, a subpopulation of peripheral blood T lymphocytes and thymocytes, follicular dendritic cells, some epithelial cells, fetal astrocytes, and chronic lymphocytic leukemia cells. CD21 is also released in soluble form in human serum as well as by human B and T lymphocytic cell lines.

CD21 (complement receptor type 2; CR2) is a type I membrane glycoprotein that functions as the receptor for complement C3 fragments iC3b, C3dg and C3d, low-affinity IgE receptor CD23, type I cytokine, interferon-alpha as well as the Epstein-Barr virus gp350/220 envelope protein ^{1, 2, 3} CD21 is part of a molecular complex that includes CD19, Leu 13 and TAPA-1 ¹ . CD21 enhances B cell proliferation and modulates the immune response ¹ . By binding to C3d, CD21 links the innate complement-mediated immune response against pathogens and foreign antigens to the adaptive immune response ³ . Additionally, the CD19/CD21 complex functions synergistically with the B cell Ag receptor (BCR) to reduce the threshold for B cell activation. CD21 is also required for the extracellular trapping of HIV by lymph node cells, and disruption of this process reduces HIV reservoirs ⁴ . Furthermore, CD21 affects the ability of CD19-CAR-T cells to recognize malignant B cells that are CD19-positive and impairs its antitumor function ⁵ .

Bu32 was produced in mouse at the University of Birmingham, England, and was shown to be specific to CD21 antigen via tests on cell lines, histological tissue sections, and blood cells ^{6, 7, 8, 9} . Bu32 was authenticated in the IVth and Vth International Leukocyte Workshops ⁹ .

C3d, EBV

1 Frémeaux-Bacchi V, Bernard I, Maillet F, et al. Eur J Immunol. 26(7):1497-1503. 1996.
2 https://www.uniprot.org/uniprotkb/P20023/entry
3 Hannan JP. Curr Protein Pept Sci. 17(5):463-487. 2016.
4 Ho J, Moir S, Kulik L, et al. J Immunol. 178(11):6968-6974. 2007.
5 Li D, Xu Q, Hu Y, et al. J Leukoc Biol. 112(4):913-918. 2022.
6 Ling N, Hansel T, Richardson P, et al. Clin Exp Immunol. 84(1):16-22. 1991.
7 Ling NR, Brown B, Hardie D. J Immunol Methods. 173(1):11-17. 1994.
8 Ling NR, Brown B, Hardie D. Clin Exp Immunol. 101(2):369-375. 1995.
9 Ling NR, Hardie DL, Johnson GD, et al. Clin Exp Immunol. 113(3):360-366. 1998.
10 Maeda K, Matsuda M, Suzuki H, et al. J Histochem Cytochem. 50(11):1475-1486. 2002.
11 Wang C, Hillsamer P, Kim CH. BMC Immunol. 12:53. 2011.
12 Jackson HM, Foley KE, O'Rourke R, et al. BMC Genet. 21(1):101. 2020.
13 Herishanu Y, Kay S, Dezorella N, et al. J Immunol. 190(2):784-793. 2013.
14 Björck P, Elenström-Magnusson C, Rosén A, et al. Eur J Immunol. 23(8):1771-1775. 1993.